A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)
TYR300-202
Phase 2 other active
Quick answer
A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) for Non-muscle invasive bladder cancer (NMIBC) is a Phase 2 program (other) at Tyra Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Tyra Biosciences
- Indication
- Non-muscle invasive bladder cancer (NMIBC)
- Phase
- Phase 2
- Modality
- other
- Status
- active